Neuroscience letters
-
Neuroscience letters · Jan 2020
Additional seizure reduction by replacement with Vagus Nerve Stimulation Model 106 (AspireSR).
AspireSR is a novel vagus nerve stimulation (VNS) device which detects ictal heart rate changes and automatically apply additional stimulus. We investigated the difference of the efficacy between AspireSR and preceding VNS models in patients with device replacement. We retrospectively reviewed the clinical data of 17 patients whose VNS devices were changed because of battery discharge. ⋯ The device parameters were low setting in AspireSR compared to preceding VNS models. AspireSR decrease significantly seizure frequencies compared to the preceding VNS models. Change of the devices to AspireSR at the time of battery empty could be recommendable.
-
Neuroscience letters · Jan 2020
Clinical TrialInvestigation of the effects of transcranial direct current stimulation and neurofeedback by continuous performance test.
Transcranial direct current stimulation (tDCS) is a noninvasive neuromodulation technique based on weak direct current stimulation through the scalp. Neurofeedback (NFB) is a learning strategy that may help alter to brain wave parameters, by monitoring electroencephalography (EEG) feedback via special programs. We aimed to investigate the supportive effects of tDCS in addition to NFB training. 16 healthy volunteers were divided equally into two groups. ⋯ NFB training shows its effects at the end of 10 sessions. Despite an increase in the latencies of correct and commission responses on the task of CPT, additional use of tDCS improves cognitive performance. Also, tDCS has a supportive effect on the healthy participants who have mild anxiety and depression; also inhibition deficits of subjects were clear.
-
Neuroscience letters · Jan 2020
Cerebrospinal fluid levels of alpha-synuclein, amyloid β, tau, phosphorylated tau, and neuron-specific enolase in patients with Parkinson's disease, dementia with Lewy bodies or other neurological disorders: Their relationships with cognition and nuclear medicine imaging findings.
Parkinson's disease (PD) and dementia with Lewy bodies (DLB) are common neurodegenerative disorders, but no established biochemical markers for these diseases have been identified. We enrolled 78 subjects (27 patients with PD/DLB, 34 patients with non-PD/DLB neurodegenerative disorders [non-PD/DLB], and 17 controls). Cerebrospinal fluid (CSF) was collected via the standard lumbar puncture technique. ⋯ Multivariate analysis revealed that the mini-mental state examination score was correlated with the CSF amyloid β42 level. The specific binding ratio on 123I-ioflupane imaging was decreased in the PD/DLB group, but it was not correlated with the CSF alpha-synuclein level. These results indicate that (1) the CSF alpha-synuclein level is a useful biomarker of PD/DLB; (2) the CSF levels of tau, p-tau, and NSE can be used to discriminate PD/DLB from non-PD/DLB; and (3) the CSF amyloid β42 level is an independent predictor of cognitive decline in neurological disorders.